RNAi Therapeutics and Technology Market Top Players - Alnylam, Novartis, Novo Nordisk, Regulus therapeutics, miRagen therapeutics.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "RNAi Therapeutics and Technology Market by Type (Small interfering RNA (siRNA), MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Infectious Diseases, Renal Diseases, Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the RNAi Therapeutics and Technology Market is valued at USD 1.6 Bn in 2023, and it is expected to reach USD 5.28 Bn by the year 2031, with a CAGR of 16.0% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2508

RNA interference (RNAi) is an advanced biological mechanism that plays a pivotal role in gene regulation through sequence-specific gene silencing. This naturally occurring process has laid the foundation for the development of RNAi-based therapeutics-an emerging class of treatments that leverage the cell's intrinsic gene-silencing functions to modulate gene expression with high precision. These therapeutics are gaining significant traction in biomedical research and development due to their applicability across a wide range of medical conditions, including cancer, metabolic disorders, and chronic diseases.

RNAi therapies offer a highly targeted approach to disease management by utilizing the body's own cellular machinery to selectively suppress the expression of disease-associated genes. This class of therapeutics includes various modalities such as antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and microRNAs (miRNA), each operating through distinct mechanisms to modulate gene activity, influence protein synthesis, and silence pathological gene expressions. The ability to precisely intervene in gene expression pathways positions RNAi-based therapeutics as a transformative innovation in modern medicine, with the potential to address complex and previously untreatable conditions.

List of Prominent Players in the RNAi Therapeutics and Technology:
• Alnylam Pharmaceuticals, Inc. (U.S.)
• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals, Inc.
• Benitec Biopharma
• Dicerna Pharmaceuticals (Novo Nordisk A/S)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Glaxosmithkline Plc.
• Ionis Pharmaceuticals (U.S.)
• Moderna, Inc.
• Olix Pharmaceuticals, Inc.
• Quark Software Inc. (U.S.)
• Rexahn Pharmaceuticals, Inc.
• Sanofi
• Silence Therapeutics
• Thermo Fisher Scientific Inc.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers
The global RNA interference (RNAi) therapeutics market is experiencing notable growth, primarily driven by the increasing prevalence of chronic diseases such as cardiovascular disorders, cancer, diabetes, tuberculosis, and AIDS. RNAi-based therapies hold substantial promise in addressing a diverse array of chronic, genetic, and rare medical conditions. According to the World Health Organization (WHO), cardiovascular diseases alone are responsible for approximately 17.9 million deaths annually, followed by cancer (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2 million). The urgent need for innovative treatment modalities is accelerating the adoption of RNAi technology, which is becoming instrumental in advancing personalized medicine and molecular diagnostics. Furthermore, the integration of high-throughput technologies that enable the identification of disease-related molecular alterations is expanding the use of RNAi in cancer diagnostics and therapeutics, reinforcing the shift toward precision medicine.

Challenges
Despite its strong therapeutic potential, the RNAi therapeutics market faces considerable challenges, particularly in the area of drug delivery. Delivering RNA molecules to target cells can trigger immune responses, thereby reducing therapeutic effectiveness. Additionally, RNA molecules are highly prone to degradation by RNases in biological tissues, which adversely impacts their stability. The inherent negative charge of RNA further complicates intracellular delivery, as it impedes passage through the hydrophobic cytoplasmic membrane, limiting cellular uptake. Large-scale production also poses a challenge due to the complex and resource-intensive nature of RNA manufacturing processes. Immunogenic responses to exogenous RNA can result in cytotoxicity and interfere with the translation of therapeutic proteins, creating additional obstacles in clinical development and regulatory approval.

Regional Trends
North America-particularly the United States-maintains a leading position in the RNAi therapeutics market, supported by a confluence of favorable factors. The region's high burden of chronic illnesses, including cancer, cardiovascular disease, and neurodegenerative disorders, continues to drive demand for novel treatment strategies. Notably, around 40% of adults in the U.S. are affected by multiple chronic conditions, underscoring the growing need for RNAi-based interventions. Significant financial support from pharmaceutical companies, government institutions, and private investors is fueling research, development, and commercialization efforts. The gene editing and RNAi sectors have also garnered substantial interest from venture capital and federal funding initiatives, further propelling industry growth. Additionally, the presence of a robust regulatory environment-exemplified by the U.S. Food and Drug Administration (FDA)-facilitates the timely evaluation and approval of RNAi-based therapies, solidifying North America's leadership in this emerging field.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2508

Recent Developments:
• In April 2024, Medison Pharma and Alnylam Pharmaceuticals, Inc. expanded their partnership to include selected markets in LATAM, APAC, and additional international markets, in addition to Central & Eastern Europe and Israel. This collaboration will allow companies to expand their footprint and provide the advantages of Alnylam's innovative RNAi treatments to patients in more APAC and LATAM regions.
• In November 2021, Arrowhead Pharmaceuticals linked an exclusive license deal with GlaxoSmithKline (GSK) for their experimental RNA interference (RNAi) therapeutic, ARO-HSD. GSK will lead the development and commercialization of ARO-HSD for treating nonalcoholic steatohepatitis (NASH). ARO-HSD targets HSD17B13 and holds promise as a therapy for both alcohol-related and nonalcohol-associated liver diseases, including NASH.

Segmentation of RNAi Therapeutics and Technology Market-
By Type
• Small interfering RNA (siRNA)
• MicroRNA (miRNA)
By Application
• Genetic Disorders
• Oncology
• Neurodegenerative Disorders
• Infectious Diseases
• Renal Diseases
• Others
By Route of Administration
• Intradermal Injections
• Pulmonary Delivery
• Intravenous Injections
By End-User
• Diagnostic Laboratories
• Research and Academic Laboratories
• Hospitals
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

View Overview Report: https://www.insightaceanalytic.com/report/rnai-therapeutics-and-technology-market/2508

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.